Dual-Eligible Medicare Beneficiaries Less Likely to Receive Recommended Chemotherapy
the Cancer Therapy Advisor take:
Patients with cancer who are dual-eligible Medicare beneficiaries are less likely to receive recommended chemotherapy compared to those with other types of supplemental Medicare coverage, according to a recent study published in the Journal of Clinical Oncology.
Joan Warren, PhD, of the National Cancer Institute (NCI) in Bethesda, and fellow colleagues examined 1,200 Medicare patients that were diagnosed with various forms of cancer from 2000 to 2005 as part of a retrospective, observational study. They cross-examined patient data acquired from the NCI’s Patterns of Care Studies with SEER-Medicare data in order to determine supplemental insurance status of each patient.
They found that dual-eligible patients with cancer were significantly less likely to receive chemotherapy compared to those Medicare patients covered under private insurance.
In addition, patients who were only covered under Medicare and saw an oncologist were found to have comparable rates of chemotherapy with Medicare patients who had private insurance.
“With the increasing number of Medicaid patients under the Affordable Care Act, there will be a need for patient navigators and sufficient physician reimbursement so that low-income patients with cancer will have access to oncologists and needed treatment,” the authors concluded.
Patients with cancer who are dual-eligible Medicare beneficiaries are less likely to receive recommended chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy